SCORE Study report 3: study design and baseline characteristics - Wikidata - wikimedia - TriplyDB

SCORE Study report 3: study design and baseline characteristics

SCORE Study report 3: study design and baseline characteristics

http://www.wikidata.org/entity/Q33484531

about

Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion Macular grid laser photocoagulation for branch retinal vein occlusion A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9.Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.Baseline predictors of visual acuity and retinal thickness in patients with retinal vein occlusion The mean platelet volume in patients with retinal vein occlusion.Effect of optical coherence tomography scan decentration on macular center subfield thickness measurements.Intravitreal Corticosteroids in the Management of Diabetic Macular Edema SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.Treatments for macular oedema following central retinal vein occlusion: systematic review.Score Study Report 12: Development of venous collaterals in the Score Study.Intravitreal injections: a review of the evidence for best practice.Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13.Automated detection of foveal center in SD-OCT images using the saliency of retinal thickness maps.

P2860

Q24187275-BC144A6F-422F-4D87-811F-D466CD75549C Q24187991-31DC40EB-3012-43A8-9C23-0AD52CC5B511 Q24646760-1042D7CE-2707-48C0-BE0C-BD28B38EE08F Q33711660-3E8C5B19-8064-4F53-A134-DBCFDEC2A6D4 Q33995887-6FDBFFC1-4F63-43B2-B871-91DAB44EF83C Q34245848-1F9E4F49-0AEF-4D9E-A9A2-612146433AAF Q35036495-9F3077CB-B50F-400B-BFAA-82BF89514957 Q35085700-CA326021-FE1F-4401-B506-B49031815877 Q35198601-EED7819E-BD63-471C-AB0D-5CA6066EA413 Q36921444-8F42B33C-4DFD-471A-A53F-BD44869F8583 Q36979246-4B0E7828-B81E-4296-B0E6-0E550A71084F Q37287831-9E3FA63F-329B-492A-A1D3-71A0C24B9D04 Q37427372-6B904BBE-D97F-434B-9024-FEAFA307CA0F Q37590692-3E797CDF-9A2F-4B2D-89DA-D5E31E0BAE59 Q38042851-A35EA51C-2AD3-4646-9143-E6568BB75813 Q38053198-80B89A77-94B9-4641-A33B-FD3DC8B7E00C Q38376975-7F13947B-6A29-4516-ADFC-A5EA9B21574F Q38792697-85B86A7D-A5D4-4EE5-8E60-5F3B75BC9447 Q41895064-A5792751-DA26-460D-A86E-CA009AEBD6B9 Q47602625-75A4ED69-D3D4-42EE-B049-EB9F25982DC7

P2860

SCORE Study report 3: study design and baseline characteristics

http://www.wikidata.org/entity/Q33484531

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

SCORE Study report 3: study design and baseline characteristics

@ast

SCORE Study report 3: study design and baseline characteristics

@en

type

label

SCORE Study report 3: study design and baseline characteristics

@ast

SCORE Study report 3: study design and baseline characteristics

@en

prefLabel

SCORE Study report 3: study design and baseline characteristics

@ast

SCORE Study report 3: study design and baseline characteristics

@en

P1433

Q33484531-5EE285C7-ACCA-49E2-9116-9BDB104B10CE

P1476

Q33484531-E18A4A9D-0046-4498-B18A-78876CF5613A

P2093

Q33484531-1FF4FF67-FD22-4BDA-BD6F-04920F88492E

Q33484531-503A4415-F508-4A13-99B9-E075ABC7358C

Q33484531-76366119-AFE9-4BE4-BDBF-7300E1C50ECD

Q33484531-AC71FDD4-974E-4A30-B050-711B8CB78C90

Q33484531-B38DE270-05B0-46F4-A3AC-2922B164D465

Q33484531-C1C41C39-3B61-49B2-9D73-0A03BCD8144B

Q33484531-CBC9769B-55F5-4AEF-827E-1922C8F6C048

Q33484531-E22FEAAA-67CB-4715-873A-53BF8E178805

Q33484531-E427C45B-9041-47B6-8156-0444601DEA3D

P2860

Q33484531-0281648B-E857-4174-89F8-8644774DC19D

Q33484531-0431ED5E-EA19-4D99-80EB-32287D5EBDF7

Q33484531-0D349A66-AB6F-4215-853C-B923C839659E

Q33484531-10CA458B-84CB-49B2-8DD8-1A217AC1FDFD

Q33484531-30B6F777-01DD-41CF-B701-FD29A108402A

Q33484531-331DDD82-B2D5-4919-ABE5-FBFB190E595C

Q33484531-380A469B-2952-4E2A-8A63-9C630C05DAD4

Q33484531-3EFF4463-BD2E-445B-B47D-41A2FD6F86D9

Q33484531-4194AF8C-B404-4343-BE5E-90FDC3198576

Q33484531-47F6DEAA-7BBF-434D-B904-50FE2DE02919

P304

Q33484531-62AC6D59-032E-4980-A909-4E50CDC81B9B

P31

Q33484531-97EDCB68-4069-4BAF-B13D-6F4C8B02EBB9

P356

Q33484531-04721DC5-36D5-4283-80B7-0642515F4455

P433

Q33484531-14837433-93C0-4417-8567-770550A9DF31

P478

Q33484531-7E8265F5-9C33-40C4-AA99-648AA9AF0E7F

P577

Q33484531-E6C9155A-BC81-4E01-A8B8-FFD689A2BD7F

P5875

Q33484531-F2948352-8FEE-4E56-97E5-A52DC96A7FA3

P698

Q33484531-DEF815D7-0A73-45B3-B52A-4F8C105BA6E8

P932

Q33484531-12E10A30-BB72-4122-BF2B-A2FF1E06099A

P356

J.OPHTHA.2009.03.022

P1433

P1476

SCORE Study report 3: study design and baseline characteristics

@en

P2093

Andrew Antoszyk

http://www.w3.org/2001/XMLSchema#string

Barbara A Blodi

http://www.w3.org/2001/XMLSchema#string

Ingrid U Scott

http://www.w3.org/2001/XMLSchema#string

Maria Figueroa

http://www.w3.org/2001/XMLSchema#string

Michael Elman

http://www.w3.org/2001/XMLSchema#string

Michael S Ip

http://www.w3.org/2001/XMLSchema#string

Neal L Oden

http://www.w3.org/2001/XMLSchema#string

Paul C VanVeldhuisen

http://www.w3.org/2001/XMLSchema#string

SCORE Study Investigator Group

http://www.w3.org/2001/XMLSchema#string

P2860

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion

Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases.

Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors.

Venous occlusive disease: management 25 years ago.

Venous occlusive disease: the latest in current management.

Interventions for central retinal vein occlusion: an evidence-based systematic review.

Interventions for branch retinal vein occlusion: an evidence-based systematic review.

Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities

Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases.

P304

1770-1777.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2009.03.022

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26683582

http://www.w3.org/2001/XMLSchema#string

P698

19619896

http://www.w3.org/2001/XMLSchema#string

P932

2785028

http://www.w3.org/2001/XMLSchema#string